Approved of GLP1

exenatide (brand names Byetta and Bydureon, manufactured by AstraZeneca), approved in 2005/2012

liraglutide (Victoza for diabetes, Saxenda for obesity, manufactured by Novo Nordisk), approved in 2010^[34]

albiglutide (Tanzeum, manufactured by GSK), approved in 2014^[35]

dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014^[36]

lixisenatide (Lyxumia in Europe, Adlyxin in the United States, manufactured by Sanofi), approved in 2016^[37]

semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for obesity, manufactured by Novo Nordisk), approved in 2017^[38]

tirzepatide (dual GLP-1 and GIP agonist; Mounjaro for diabetes, Zepbound for obesity, manufactured by Eli Lilly), approved in 2022^[39]